556 related articles for article (PubMed ID: 34792124)
21. Effects of different sodium-glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a network meta-analysis.
Lan X; Zhu H; Cao Y; Hu Y; Fan X; Zhang K; Wu M
Front Cardiovasc Med; 2024; 11():1379765. PubMed ID: 38845687
[TBL] [Abstract][Full Text] [Related]
22. Effects of empagliflozin in different phases of diabetes mellitus-related cardiomyopathy: a prospective observational study.
Oka S; Kai T; Hoshino K; Watanabe K; Nakamura J; Abe M; Watanabe A
BMC Cardiovasc Disord; 2021 Apr; 21(1):217. PubMed ID: 33926386
[TBL] [Abstract][Full Text] [Related]
23. Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial.
Connelly KA; Mazer CD; Puar P; Teoh H; Wang CH; Mason T; Akhavein F; Chang CW; Liu MH; Yang NI; Chen WS; Juan YH; Opingari E; Salyani Y; Barbour W; Pasricha A; Ahmed S; Kosmopoulos A; Verma R; Moroney M; Bakbak E; Krishnaraj A; Bhatt DL; Butler J; Kosiborod MN; Lam CSP; Hess DA; Rizzi Coelho-Filho O; Lafreniere-Roula M; Thorpe KE; Quan A; Leiter LA; Yan AT; Verma S
Circulation; 2023 Jan; 147(4):284-295. PubMed ID: 36335517
[TBL] [Abstract][Full Text] [Related]
24. Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction.
Santos-Gallego CG; Vargas-Delgado AP; Requena-Ibanez JA; Garcia-Ropero A; Mancini D; Pinney S; Macaluso F; Sartori S; Roque M; Sabatel-Perez F; Rodriguez-Cordero A; Zafar MU; Fergus I; Atallah-Lajam F; Contreras JP; Varley C; Moreno PR; Abascal VM; Lala A; Tamler R; Sanz J; Fuster V; Badimon JJ;
J Am Coll Cardiol; 2021 Jan; 77(3):243-255. PubMed ID: 33197559
[TBL] [Abstract][Full Text] [Related]
25. New-onset syncope in diabetic patients treated with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors: a Chinese population-based cohort study.
Gao X; Zhang N; Lu L; Gao T; Chou OHI; Wong WT; Chang C; Wai AKC; Lip GYH; Zhang Q; Tse G; Liu T; Zhou J
Eur Heart J Cardiovasc Pharmacother; 2024 Feb; 10(2):103-117. PubMed ID: 37962962
[TBL] [Abstract][Full Text] [Related]
26. Safety outcomes of SGLT2i in the heart failure trials: A systematic review and Meta-analysis.
Younes AM; Salem M; Maraey A; Nomigolzar S; Sewell K; Khalil M; Elzanaty A; Saeyeldin A; Dar M
Int J Cardiol; 2022 Nov; 366():51-56. PubMed ID: 35777490
[TBL] [Abstract][Full Text] [Related]
27. Contemporary Use of Sodium-Glucose Cotransporter-2 Inhibitor Therapy Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction in the US: The Get With The Guidelines-Heart Failure Registry.
Pierce JB; Vaduganathan M; Fonarow GC; Ikeaba U; Chiswell K; Butler J; DeVore AD; Heidenreich PA; Huang JC; Kittleson MM; Joynt Maddox KE; Linganathan KK; McDermott JJ; Owens AT; Peterson PN; Solomon SD; Vardeny O; Yancy CW; Greene SJ
JAMA Cardiol; 2023 Jul; 8(7):652-661. PubMed ID: 37212192
[TBL] [Abstract][Full Text] [Related]
28. Positive effect of dapagliflozin on left ventricular longitudinal function for type 2 diabetic mellitus patients with chronic heart failure.
Tanaka H; Soga F; Tatsumi K; Mochizuki Y; Sano H; Toki H; Matsumoto K; Shite J; Takaoka H; Doi T; Hirata KI
Cardiovasc Diabetol; 2020 Jan; 19(1):6. PubMed ID: 31910853
[TBL] [Abstract][Full Text] [Related]
29. Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors among patients with heart failure with preserved ejection fraction.
Riaz M; Smith SM; Dietrich EA; Winchester DE; Guo J; Park H
Pharmacotherapy; 2023 Oct; 43(10):1024-1031. PubMed ID: 37459069
[TBL] [Abstract][Full Text] [Related]
30. Effects of dapagliflozin and empagliflozin on 6-min walk distance in heart failure with preserved and reduced ejection fraction: A systematic review and meta-analysis of randomized controlled trials involving 2624 patients.
Tanashat M; Manasrah A; Abouzid M
Eur J Clin Pharmacol; 2024 Jul; 80(7):951-963. PubMed ID: 38498097
[TBL] [Abstract][Full Text] [Related]
31. Roles for SGLT2 Inhibitors in Cardiorenal Disease.
Green JB; McCullough PA
Cardiorenal Med; 2022; 12(3):81-93. PubMed ID: 35835083
[TBL] [Abstract][Full Text] [Related]
32. Sodium-glucose cotransporter 2 inhibitor effects on heart failure hospitalization and cardiac function: systematic review.
Rasalam R; Atherton JJ; Deed G; Molloy-Bland M; Cohen N; Sindone A
ESC Heart Fail; 2021 Oct; 8(5):4093-4118. PubMed ID: 34219407
[TBL] [Abstract][Full Text] [Related]
33. Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-Systematic review and meta-analysis of randomized placebo-controlled trials.
Salah HM; Al'Aref SJ; Khan MS; Al-Hawwas M; Vallurupalli S; Mehta JL; Mounsey JP; Greene SJ; McGuire DK; Lopes RD; Fudim M
Am Heart J; 2021 Feb; 232():10-22. PubMed ID: 33214130
[TBL] [Abstract][Full Text] [Related]
34. Combining sodium-glucose cotransporter 2 inhibitors and angiotensin receptor-neprilysin inhibitors in heart failure patients with reduced ejection fraction and diabetes mellitus: A multi-institutional study.
Hsiao FC; Lin CP; Tung YC; Chang PC; McMurray JJV; Chu PH
Int J Cardiol; 2021 May; 330():91-97. PubMed ID: 33587940
[TBL] [Abstract][Full Text] [Related]
35. SGLT2i versus ARNI in heart failure with reduced ejection fraction: a systematic review and meta-analysis.
Yan Y; Liu B; Du J; Wang J; Jing X; Liu Y; Deng S; Du J; She Q
ESC Heart Fail; 2021 Jun; 8(3):2210-2219. PubMed ID: 33749159
[TBL] [Abstract][Full Text] [Related]
36. Effects of SGLT2 inhibitors on cardiac function and health status in chronic heart failure: a systematic review and meta-analysis.
Chen J; Jiang C; Guo M; Zeng Y; Jiang Z; Zhang D; Tu M; Tan X; Yan P; Xu X; Long Y; Xu Y
Cardiovasc Diabetol; 2024 Jan; 23(1):2. PubMed ID: 38172861
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of SGLT2-inhibitors across different definitions of heart failure with preserved ejection fraction.
De Marzo V; Savarese G; Porto I; Metra M; Ameri P
J Cardiovasc Med (Hagerstown); 2023 Aug; 24(8):537-543. PubMed ID: 37409599
[TBL] [Abstract][Full Text] [Related]
38. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
Kato ET; Silverman MG; Mosenzon O; Zelniker TA; Cahn A; Furtado RHM; Kuder J; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Bonaca MP; Ruff CT; Desai AS; Goto S; Johansson PA; Gause-Nilsson I; Johanson P; Langkilde AM; Raz I; Sabatine MS; Wiviott SD
Circulation; 2019 May; 139(22):2528-2536. PubMed ID: 30882238
[TBL] [Abstract][Full Text] [Related]
39. Sodium glucose co-transporter 2 inhibitors and quality of life in patients with heart failure: a comprehensive systematic review and meta-analysis of randomized controlled trials.
Oriecuia C; Tomasoni D; Sala I; Bonfioli GB; Adamo M; Gussago C; Lombardi CM; Pagnesi M; Savarese G; Metra M; Specchia C
Eur Heart J Cardiovasc Pharmacother; 2024 Feb; 10(2):147-157. PubMed ID: 37985675
[TBL] [Abstract][Full Text] [Related]
40. Effects of antidiabetic drugs on left ventricular function/dysfunction: a systematic review and network meta-analysis.
Zhang DP; Xu L; Wang LF; Wang HJ; Jiang F
Cardiovasc Diabetol; 2020 Jan; 19(1):10. PubMed ID: 31969144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
